Table 1 Description of the variables and parameters used in the vascular tumour growth and the two-compartmental pharmacokinetic bevacizumab models

t

Time

day

n/a

-

V

Tumour volume

mm³

n/a

-

K

Tumour carrying capacity

mm³

n/a

-

λ ₁

Gompertzian growth constant

day⁻¹

0.192

[31, 43]

λ ₂

Proportionality constant related to the natural mortality of endothelial cells

day⁻¹

0

[31, 43]

c

Proportionality constant related to the term reflecting endogenous stimulation of the tumour upon the vasculature

mg/(day · mm^3p · kg)

5.85

[31, 43]

d

Proportionality constant related to the term reflecting endogenous inhibition of tumour vasculature

day⁻¹ · mm⁻²

0.00873

[31]

α

Parameter reflecting the stimulator clearance rate

mg/(mm^3p · kg)

1

[43]

β

Parameter reflecting the extent of the abnormal phenotype of tumour vasculature

mm^3p

1

[43]

p

Parameter reflecting the extent of the abnormal phenotype of tumour vasculature

-

0

[43]

I

Drug concentration in plasma

mg/kg

n/a

-

t

Time-point

day

n/a

-

I

Bevacizumab concentration in plasma

mg/ml

n/a

-

n

Number of infusions to be administered

-

9

[60]

D

Dose

mg

dosage*weight

-

T

Infusion duration

day

1/48

[66]

V _c

Volume of central compartment

ml

7.975

[64]

k ₁₂

Transfer constant from central to peripheral compartment

day⁻¹

0.7536

[64]

k ₂₁

Transfer constant from peripheral to central compartment

day⁻¹

0.3144

[64]

k _e

Rate of elimination

day⁻¹

0.3888

[64]

d

Dosage

mg/kg

5

[60, 61, 65]

w

Host’s weight

kg

0.025

[60, 64]

t _D

Administration time-point of anti-angiogenic treatment

day

t₁ = 1

-

t₂ = 4

t₃ = 8

t₄ = 11

t₅ = 15

t₆ = 18

t₇ = 22

t₈ = 25

t₉ = 29